Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Adaptive Eyes NGS-Based Test for T Cell Response in COVID-19

Adaptive Eyes NGS-Based Test for T Cell Response in COVID-19

May 13, 2020
|
Andrew P. Han
Premium

This story has been updated to clarify that Adaptive Biotechnologies' partnership with Amgen on COVID-19 antibody development is new.

NEW YORK – Adaptive Biotechnologies is recruiting subjects for a sequencing-based study of T cell response in people who have or have been exposed to COVID-19, with designs on making the disease an early indication for the company's planned immunoSeq Dx test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Russia Vaccine Approval Raises Concerns

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

Numbers Needed

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

PNAS Papers on Sarcoma Fusion Effects, Transfer RNA Changes in Colon Cancer, TB-T2D Interactions

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Move Away From Basic Research?

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
26
Featured Webinar

Resolving Complex Haplotypes Implicated in Alzheimer’s and Other Neurodegenerative Diseases

Sponsored by
Bionano Genomics

Alzheimer’s disease is genetically complex with no meaningful therapies or pre-symptomatic disease diagnostics. 

What's Popular?

In Molecular Diagnostics

  1. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

  2. Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

  3. Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

    Premium

  4. Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

  5. Caris Life Sciences, Elevation Oncology Partner on Patient Enrollment for Tumor-Agnostic Drug Trial

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.